

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

## OTHER RELEVANT INFORMATION

As a continuation of the Other Relevant Information note dated 11 April 2022, Grifols informs that, having obtained all regulatory approvals, it has closed the share and purchase agreement with Tiancheng International Investment Limited to acquire all the existing share capital of Tiancheng (Germany) Pharmaceutical Holdings AG ("**HoldCo**"), which owns 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG ("**Biotest**"). At the same time, the voluntary takeover launched by Grifols to acquire the remaining ordinary and preferred shares has ended and payment has been settled.

With the closing of the transaction, Grifols has paid EUR 1,091 million to Tiancheng International Investment Limited, which is composed of (i) 17,783,776 ordinary shares of Biotest valued at EUR 43.00 per share; (ii) 214,581 Biotest preferred shares valued at EUR 37.00 per share, and (iii) a receivable loan granted by HoldCo to Biotest in the amount of EUR 318 million. On the other side, the closing of the voluntary takeover bid has resulted in the payment of EUR 362 million for 1,250,298 ordinary shares and 8,340,577 preferred shares.

Following completion of the takeover and of the acquisition of the HoldCo, Grifols controls 96.20% of the voting rights of Biotest and holds 69.72% of its share capital.

The Biotest acquisition is a strategic and transformational transaction that will accelerate Grifols' growth and innovation. Likewise, it will contribute to expand and diversify Grifols' plasma supply, strengthening its operations and revenues in Europe, the Middle East and Africa, and support the company's economic performance. Furthermore, it enables Grifols and Biotest to jointly move forward to globally increase the availability of plasma-derived therapies for the benefit of patients, while allowing Grifols to strengthen its position by improving and complementing its operational, industrial and scientific capabilities, among others.

In Barcelona, on 25 April 2022

---

Nuria Martín Barnés  
Secretary to the Board of Directors